Clifford Goodman
Overview
Explore the profile of Clifford Goodman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodman C, Treloar E
Int J Technol Assess Health Care
. 2024 Nov;
40(1):e48.
PMID: 39498482
Objectives: The Health Technology Assessment International (HTAi) 2023 Annual Meeting included a novel "fishbowl" session intended to 1) probe the role of HTA in the emergence of generative pretrained transformer...
2.
Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia-Foncillas J, Goodman C, et al.
Oncologist
. 2023 Mar;
28(5):e242-e253.
PMID: 36961477
Background: Adoption of high-throughput, gene panel-based, next-generation sequencing (NGS) into routine cancer care is widely supported, but hampered by concerns about cost. To inform policies regarding genomic testing strategies, we...
3.
Wang M, Negrier C, Driessler F, Goodman C, Skinner M
Patient Prefer Adherence
. 2022 Jun;
16:1439-1447.
PMID: 35707346
Purpose: The anticipated emergence of hemophilia gene therapy will present people with hemophilia (PWH) and treating clinicians with increasingly complex treatment options. It will be critical that PWH and their...
4.
Pritchard D, Goodman C, Nadauld L
JCO Precis Oncol
. 2022 Jan;
6:e2100349.
PMID: 35085005
Purpose: In the era of personalized medicine, physicians rely on their understanding of clinical utility to assess the value of rapidly evolving genetic and genomic tests. Current definitions of the...
5.
Goodman C, Berntorp E, Wong O
Haemophilia
. 2022 Jan;
28 Suppl 2:27-34.
PMID: 35060645
Introduction: The emergence of durable and potentially curative cell and gene therapies (also known as advanced therapy medicinal products) with high price tags is challenging conventional health care payment systems....
6.
Goodman C, Villarivera C, Gregor K, Van Bavel J
J Manag Care Spec Pharm
. 2019 Sep;
25(11):1174-1181.
PMID: 31535596
Background: Although interest in outcomes-based risk-sharing agreements (OBRSAs) and other value-based contracts (VBCs) continues to grow, the number of VBCs in the United States is still limited. A better understanding...
7.
Paddock S, Goodman C, Shortenhaus S, Grainger D, Zummo J, Thomas S
Future Oncol
. 2017 Jul;
13(25):2253-2264.
PMID: 28745521
Aim: Several recently developed frameworks aim to assess the value of cancer treatments, but the most appropriate metrics remain uncertain. Methods: We use data from the Patient Access to Cancer...
8.
Bach P, Edge S, House L, Malin J, Mohler J, Goodman C
J Natl Compr Canc Netw
. 2015 May;
13(5 Suppl):659-61.
PMID: 25995423
As part of the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care, a distinguished and diverse group of experts on value-based decision-making in oncology discussed guidelines and pathways...
9.
Paddock S, Brum L, Sorrow K, Thomas S, Spence S, Maulbecker-Armstrong C, et al.
Ecancermedicalscience
. 2015 Jan;
9:498.
PMID: 25624879
Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about 'progress' and 'value' in cancer research. In times...
10.
Downs C, Fowler L, Kolodziej M, Newcomer L, Ogaily M, Purcell W, et al.
J Natl Compr Canc Netw
. 2014 May;
12(5 Suppl):745-7.
PMID: 24853209
The Affordable Care Act (ACA) is a transformational event for health care in the United States, with multiple impacts on health care, the economy, and society. Oncologists and other health...